[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aa9154e51b3d97e5e453283ca69f7982a",
    "date": "2026-05-07",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "Active_Biotech_Rapport_2026_Q1_Sve.pdf",
    "text_chars": 49140,
    "sha256": "e250c958f1f47dd069c5af84cd6f79ff434a8dd18adfbe6d65b227a9ad69c337",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 49140
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a021c93eb2bff7249e5f5fdf0518a9c4b",
    "date": "2026-04-01",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "Active_Biotech_2025_Sve.pdf",
    "text_chars": 283895,
    "sha256": "88bf9db8a8abec5d77d1333dc40e9fc0c94fa3a357c6501b67d9985bc8247a9b",
    "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 179320
      },
      {
        "number": 2,
        "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 104573
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aca159b19464ce4a453db1195556593e8",
    "date": "2026-02-12",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "Active_Biotech_Rapport_2025_Q4_Sve.pdf",
    "text_chars": 54948,
    "sha256": "51d53e436a17b0f7117d184eeec2af8688c0ff7fe40da65c08c7e7435c05d449",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 54948
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a72cf8adad377196c5f57d9153e93fe7b",
    "date": "2025-11-06",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "Active_Biotech_Rapport_2025_Q3_Sve.pdf",
    "text_chars": 62633,
    "sha256": "d1480f822f3ddd272476ed46d0c6a45cb5ba32c625da8685b3ca91513738d4a4",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 62633
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2eccc638698c9f2aea2022c142042bb7",
    "date": "2025-08-21",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "Active_Biotech_Rapport_2025_Q2_Sve.pdf",
    "text_chars": 58751,
    "sha256": "85660e7863f0fe0d042a855e88c9e3f23ad15b38847790e7a9faeee8a7ee3425",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 58751
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aecd93218278374230f26f6f12d3c90ea",
    "date": "2025-05-08",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "Active_Biotech_Rapport_2025_Q1_Sve.pdf",
    "text_chars": 57126,
    "sha256": "2a217ea547a4d70cd9d87ff1aa88f1542037927c5188e4337bea8524a4c46526",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 57126
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ab29fe1da63c9680f3d6aad7159c9a6da",
    "date": "2025-04-07",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "Active_Biotech_2024_Sve.pdf",
    "text_chars": 307165,
    "sha256": "97a68ebdc4b298c49c560a2d6c993da29fdb93c16e92d9b0b3b6789ccc1e917e",
    "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 179118
      },
      {
        "number": 2,
        "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 128045
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a3ec16aacb121a02bfd3f46ba313c9765",
    "date": "2025-02-13",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "Active_Biotech_Rapport_2024_Q4_Sve.pdf",
    "text_chars": 62464,
    "sha256": "1d489c064de78126550f227dfaa46219d75dcc06c14bea92c16e7282d4d53600",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 62464
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a4bc6d31be9beb9745e1e34b0e4a1edc4",
    "date": "2024-10-21",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "AB_Rapport_2024_Q3_Sv.pdf",
    "text_chars": 63888,
    "sha256": "77a80580a0321f6c96d9a9f0e4c774c403e922a97bb83990046a2a7ec0f28e58",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 63888
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac3cca813fd679370e9c4112973da021a",
    "date": "2024-08-22",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "AB_Rapport_2024_Q2_Sv.pdf",
    "text_chars": 55542,
    "sha256": "f362dcc495266d00e8080a3417b90aacf73918d44a5706df3b43740adc2c07da",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 55542
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a17370e61d30ce886f91e99fb458bf4a7",
    "date": "2024-05-08",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "AB_Rapport_2024_Q1_Sv.pdf",
    "text_chars": 59047,
    "sha256": "84816ad79acd600c1002df056671c601cd5f3a9014bfa8a375e6691dfc05cd20",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 59047
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae773646c51c9e2f2a2f1168fc7e5e9ac",
    "date": "2024-04-22",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "Active_Biotech_2023_Sve.pdf",
    "text_chars": 309681,
    "sha256": "dc8762605d28fa90683f0dd2f7360f7014cb8a2b80a66c487a1e0c0e45bfe00b",
    "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 179795
      },
      {
        "number": 2,
        "url": "/company/active-biotech/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 129884
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8f42024facc84fdf446634de9530a785",
    "date": "2024-02-08",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "Ab_Rapport_2023_Q4_Sve.pdf",
    "text_chars": 60458,
    "sha256": "ebce3b66d7388f46aa065db4f459da99c780abd5e9e1d65e7b797b6e9110c902",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 60458
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/acb03ff15ede6f7e732c107c1215c31a2",
    "date": "2023-11-09",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "AB_Rapport_2023_Q3_Sve.pdf",
    "text_chars": 57125,
    "sha256": "0ab6e23509f4801ef2e4592682fcfbdde699b9c747c21cb5f55148a17450a0b4",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 57125
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7c98e6507d7d6797788f40ef09b5d08c",
    "date": "2023-08-24",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "AB_Rapport_2023_Q2_Sve.pdf",
    "text_chars": 54776,
    "sha256": "c636f03354ee1882c569d5de9cded35144067806557ae0a625d1ba32984715d8",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 54776
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad79d1d4f816db9df4983e5c20a487f00",
    "date": "2023-05-04",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "Ab_Rapport_2023_Q1_Sv.pdf",
    "text_chars": 49168,
    "sha256": "1df5459e6d41478ac51332604cb705bb83ffdeba18557359b0ecd6e222cccb10",
    "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 49168
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/active-biotech",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 14197,
    "sha256": "7a26fad74b31f89ddd6760f51f1da93a73b1d400b1d7705db0224c260a50df7a",
    "url": "/company/active-biotech/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/active-biotech/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/active-biotech/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/active-biotech/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/active-biotech/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 14197
      }
    ]
  }
]